UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
Lorenz Bastian, Alina Hartmann, Thomas Beder, Sonja Hänzelmann, Jan Christian Kässens, Miriam Bultmann, Marc P. Hoeppner, Sören Franzenburg, Michael Wittig, André Franke, Inga Nagel, Malte Spielmann, Niklas Reimer, Hauke Busch, Stefan Schwartz, Björn Steffen, Andreas Viardot, Konstanze Döhner, Mustafa Kondakci, Gerald Wulf, Knut Wendelin, Andrea Renzelmann, Alexander Kiani, Heiko Trautmann, Martín Neumann, Nicola Gökbuget, Monika Brüggemann, Claudia D. Baldus
Abstract
Genomic aberrations—gene fusions in the majority of cases—and corresponding transcriptional regulations define an increasingly complex landscape of molecular subtypes in B cell precursor acute lymphoblastic leukemia (BCP-ALL) [1]. Up to 15% of patients cannot be allocated to established subtypes, suggesting the presence of unrecognized drivers—especially in adult patients who have been less studied so far.